Ockham Biotech Ltd. is a research company which is focussed on the development of inhaled heparin for the treatment of obstructive airway diseases, including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma.
Ockham Biotech Ltd are seeking partners for the commercialisation of inhaled heparin in COPD, bronchiectasis, asthma, cystic fibrosis and other diseases characterised by airway obstruction with mucus.